AUSTIN, Texas–(BUSINESS WIRE)–Elevage Medical Technologies (“Elevage” or the “Company”), a strategic growth partner to innovative medical technology companies, today announced that its Board of Directors (the “Board”) has promoted Michael Wasserman, Ph.D., from Chief Operating Officer to Chief Executive Officer, effective immediately. Dr. Wasserman succeeds Evan Melrose, M.D., who has been terminated from all positions relating to Elevage, the Board and the companies with which Elevage has partnered.
The Company’s strategy, investment approach, and commitment to its partnership companies remain unchanged. Dr. Wasserman brings more than 30 years of health care experience as a scientist, entrepreneur, executive, and investor. Before joining Elevage, he was Managing Partner of Maverix Private Equity and spent 17 years at H.I.G. Capital as a Managing Director in the firm’s BioHealth platform. Throughout his career, Dr. Wasserman has partnered with management teams and portfolio companies across R&D, product development, commercialization, financing, and corporate strategy, and has served on the boards of numerous growth-stage medical technology companies.
“I am honored to lead Elevage and continue our mission of helping innovative medical technology companies navigate critical growth stages,” said Dr. Wasserman. “Our focus remains on partnering with exceptional management teams and providing the capital, strategic support, and operational expertise that help breakthrough technologies reach more patients and improve health outcomes and quality of life.”
“Elevage currently has meaningful momentum, and Michael has been instrumental in shaping the culture and approach since he joined at inception,” said Jim Momtazee, Chairman of the Board of Directors of the Company. “We have a lot of confidence in Michael and the entire team at Elevage and look forward to continuing to aid in the expansion of a number of promising medical technologies.”
About Elevage Medical Technologies
Elevage Medical Technologies is a platform established by Patient Square Capital dedicated to supporting medical technology companies that can meaningfully improve health outcomes and quality of life for patients. Elevage provides capital along with deep technical, regulatory, and operational expertise to companies ranging from advanced clinical development to commercial acceleration stage. Elevage supports rapidly growing, highly differentiated companies with paradigm shifting technologies and strives to help build industry-leading medical technologies. To learn more about Elevage, please visit www.elevagemedical.com.
Contacts
Media Contact
Prosek Partners
[email protected]
